Health Policy Modelling

Health care providers and government are increasingly turning to modelling studies to inform their decisions to adopt or reimburse new drugs, procedures or programs of care. Modelling allows useful comparisons across conditions, technologies and drug therapies.

Models may be linked to primary research studies or use existing trial data. They may focus on one specific research question or be designed to answer a set of policy questions. THETA investigators use a variety of decision models including: simple decision trees, Markov models, simulation models and dynamic infectious disease models.

THETA investigators have particular interest in:

• refining Markov modelling methods
• developing comprehensive health policy models, and
• using dynamic models for infectious disease modelling.

Grants

Krahn, Murray, Pham, Ba', Tricco A, Hoch, Jeffrey S, Tomlinson, George. Markov Models for Cost Effectiveness Analysis: A Framework for Assessing External Consistency. Canadian Coordinating Office for Health Technology Assessment (CCOHTA) $41,135.

Krahn, Murray, Rosen B, Lachlin M, Sander, Beate, Grootendorst, Paul, Tomlinson, George, Anonychuk A, Sampson M, Tricco A, Pham, Ba'. Liquid-Based Techniques for Cervical Cancer Screening. CCOHTA Request for Proposal - Project # 05-P-H0333. Canadian Agency for Drugs and Technologies in Health, $55,0000.

Krahn, Murray, Holowaty E, Naglie, Gary, Irvine J, Ritvo P, Mamdani, Muhammad, Alibhai, Shabbir, Trachtenberg J, Laporte, Audrey. Population-based estimates of cost and quality of life in prostate cancer survivors. Canadian Institutes for Health Research $726,826.

Publications

Bremner, Karen E., Bayoumi, Ahmed M., Sherman E, Krahn, Murray. Biopsy vs immediate resection for solitary 1-2 cm liver nodules in patients with cirrhosis: A decision analysis. Can J Gastroenterology 2007 August; 21(8):491-500.

Lopushinsky S, Fowler, Robert, Fecteau A, Grant D, Wales P. The Optimal Timing of Intestinal Transplantation for Children with Intestinal Failure: A Markov Analysis. Annals of Surgery 2007 (Accepted); :.

Bauch C, Rao ASRS, Pham, Ba', Krahn, Murray, Gilca V, Duval B, Chen M, Tricco A. A dynamic model for assessing universal Hepatitis A vaccination in Canada. Vaccine 2007; 25:1719-1726.

Kulkarni G, Finelli A, Fleshner NE, Jewett MAS, Lopushinsky S, Alibhai, Shabbir. Immediate cystectomy versus conservative management with delayed cystectomy for T1G3 bladder cancer: a decision analysis. PLoS Medicine 2007; 4(9):e284.

Temple LK, Naimark, David M.J., McLeod RS. Decision analysis as an aid to determining management of early low rectal cancer for the individual patient. Journal of Clinical Oncology 1999; 17(1):312-8.

Naimark, David M.J., Krahn, Murray, Naglie, Gary, Redelmeier D, Detsky, Allan. Primer on Medical Decision Analysis: Part 5. Working With Markov Processes. Medical Decision Making 1997; 17:142-51.

Krahn, Murray, Naglie, Gary, 13Redelmeier D, Detsky, Allan. Primer on Medical Decision Analysis: Part 4. Sensitivity Analysis. Medical Decision Making 1997; 17:142-51.

Naglie, Gary, Krahn, Murray, Naimark, David M.J., Redelmeier D, Detsky, Allan. Primer on Medical Decision Analysis: Part 3. Utility Measures. Medical Decision Making 1997; 17:136-41.

Detsky, Allan, Naglie, Gary, Krahn, Murray, Naimark, David M.J., Redelmeier D. Primer on Medical Decision Analysis: Part 2. Tree Structure. Medical Decision Making 1997; 17:126-35.

Detsky, Allan, Naglie, Gary, Krahn, Murray, Naimark, David M.J., Redelmeier D. Primer on Medical Decision Analysis: Part 1. Introduction. Medical Decision Making 1997; 17:123-5.

Redelmeier D, Detsky, Allan, Krahn, Murray, Naimark, David M.J., Naglie, Gary. Guidelines for verbal presentations of medical decision analyses. Medical Decision Making 1997; 17(2):228-30.

Naimark, David M.J., Naglie, Gary, Detsky, Allan. The Meaning of Life Expectancy: What is a Clinically Significant Gain. Journal of General Internal Medicine 1994; 9:702-7.

Team